Naesens Janwillem 4
4 · Cyteir Therapeutics, Inc. · Filed Jun 24, 2021
Insider Transaction Report
Form 4
Naesens Janwillem
10% Owner
Transactions
- Conversion
Common Stock
2021-06-22+3,259,026→ 3,259,026 total(indirect: See Footnote) - Purchase
Common Stock
2021-06-22$18.00/sh+277,777$4,999,986→ 3,536,803 total(indirect: See Footnote) - Conversion
Series B Convertible Preferred Stock
2021-06-22−10,000,000→ 0 total(indirect: See Footnote)→ Common Stock (2,933,583 underlying) - Conversion
Series C Convertible Preferred Stock
2021-06-22−1,109,368→ 0 total(indirect: See Footnote)→ Common Stock (325,443 underlying)
Footnotes (2)
- [F1]Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
- [F2]Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by the Reporting Person) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. The Reporting Person, along with Mr. Verelst, disclaim beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein.